Wednesday, July 8, 2026

biotech · Malignant Glioma · Prostate Cancer · CADL

Candel Therapeutics

Candel Therapeutics clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

117 Kendrick Street, Suite 450, Needham, Massachusetts 02494, US HQ
1999 Founded
82 Employees
Public company Type
CADL · NYSE Ticker
Company details
Status
Public
HQ
117 Kendrick Street, Suite 450, Needham, Massachusetts 02494, US
Founded
1999
Employees
82
Programs
12
Drugs
4
Patents
0
Intelligence · Clinical Programs

Candel Therapeutics projects

1 ClinicalTrials.gov programs sponsored by Candel Therapeutics.

Candel Therapeutics has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Aglatimagene besadenovec + valacyclovir

    Candel Therapeutics

    Prostate Cancer

    phase 3 mab active

    1 trial

Frequently asked questions

How many clinical projects does Candel Therapeutics have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.